Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was up 0.5% during mid-day trading on Monday . The stock traded as high as $8.10 and last traded at $8.10. Approximately 42,728 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 45,683 shares. The stock had previously closed at $8.06.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Prenetics Global to a "hold" rating in a report on Saturday, July 5th.
Check Out Our Latest Research Report on PRE
Prenetics Global Trading Down 4.0%
The stock's fifty day moving average is $8.38 and its two-hundred day moving average is $6.17. The company has a market capitalization of $100.58 million, a PE ratio of -1.94 and a beta of 0.15.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings results on Thursday, June 12th. The company reported ($0.80) earnings per share for the quarter. The company had revenue of $17.31 million during the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%. As a group, analysts anticipate that Prenetics Global Limited will post -3.3 EPS for the current fiscal year.
Hedge Funds Weigh In On Prenetics Global
A hedge fund recently raised its stake in Prenetics Global stock. Nomura Holdings Inc. grew its stake in shares of Prenetics Global Limited (NASDAQ:PRE - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 333,528 shares of the company's stock after buying an additional 10,576 shares during the period. Nomura Holdings Inc. owned 2.73% of Prenetics Global worth $1,307,000 at the end of the most recent reporting period. 25.01% of the stock is currently owned by institutional investors and hedge funds.
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Featured Articles
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
